Effective VA-ECMO Intervention for Severe Cardiotoxicity Induced by Neoadjuvant Paclitaxel and Cisplatin in Laryngeal Cancer: A Case Study

1

Severe cardiotoxicity from neoadjuvant paclitaxel and cisplatin in laryngeal cancer is rare but can lead to fulminant myocarditis and cardiogenic shock.
2

VA-ECMO provides critical mechanical circulatory support for patients experiencing refractory cardiogenic shock due to chemotherapy-induced cardiotoxicity.
3

The case study highlights a 59-year-old male who developed severe cardiac complications after three cycles of TP chemotherapy.
4

Despite initial interventions, the patient's condition deteriorated, necessitating transfer for VA-ECMO support to manage cardiogenic shock.
5

This report emphasizes the potential life-saving role of VA-ECMO in treating severe cardiotoxicity from commonly used chemotherapy regimens.

Bmc Cardiovascular Disorders

by Yan Qian, Youjun Pan, Zhiru Che, Ke Fang, Yingya Cao, Xiaogan Jiang, Weihua Lu, Qiancheng Xu
December 15, 2025

1